|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 14-09-16 | CHUGAI PHARMACEUTICAL : Roche's $8 billion InterMune buy not a signal for more big deals | RE |
| 14-09-04 | Roche : rules out mega deals, open to smaller ones - paper | RE |
Executive Committee: InterMune Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Mark Thompson
CEO | Chief Executive Officer | 57 | - |
| Chief Tech/Sci/R&D Officer | 71 | 2002-03-31 | |
Carla Fiankan
LAW | General Counsel | - | 2011-07-31 |
Company details: InterMune Inc
Other Biotechnology & Medical Research
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.28% | +5.03% | +10.89% | +36.56% | 47.97B | |
| -1.69% | +1.48% | +50.57% | +33.71% | 44.5B | |
| +2.56% | +7.34% | +366.69% | +609.24% | 43.93B | |
| +0.24% | +2.85% | +10.67% | +87.77% | 41.03B | |
| -0.62% | -1.11% | +4.65% | +46.13% | 29.85B | |
| -0.28% | +1.07% | +24.58% | +149.55% | 17.27B | |
| +3.37% | +9.21% | +8.32% | - | 15.34B | |
| +1.29% | +0.38% | +28.88% | +47.74% | 15.3B | |
| -2.21% | -4.70% | - | - | 14.82B | |
| Average | -0.20% | +2.35% | +63.16% | +144.38% | 30B | |
| Weighted average by Cap. | +0.13% | +2.86% | +80.14% | +159.72% |
- Stock Market
- Stocks
- Stock
- Company InterMune Inc
Select your edition
All financial news and data tailored to specific country editions
